Previous 10 | Next 10 |
LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated virus (AAV) gene therapy candidate in Gaucher disease Type 1, on Tuesday, August 1, 2023 at 8:3...
2023-07-13 10:09:11 ET Gainers: Applied DNA Sciences ( APDN ) +29% . 60 Degrees Pharmaceuticals ( SXTP ) +21% . Exicure ( XCUR ) +13% . Psychemedics ( PMD ) +11% . Plus Therapeutics ( PSTV ) +9% . Losers: First W...
2023-07-13 08:30:54 ET Ault Alliance ( AULT ) -35% announces a second partial distribution of TOG securities of approximately $0.37 for each share of ault alliance common stock. First Wave BioPharma ( FWBI ) -34% after Phase 2 setback for gut therapy. Cryop...
Freeline Therapeutics Holdings PLC (NASDAQ: FRLN) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 41.78% on the day to $5.26. Freeline Therapeutics Holdings PLC, a clinical-stage biotechnology company, develops tra...
2023-07-12 08:24:50 ET Ault Alliance ( NYSE: AULT ) +152% . Healthcare Triangle ( HCTI ) +127% . Cadrenal Therapeutics ( CVKD ) +61% . Liminal BioSciences ( LMNL ) +40% to go private in buyout deal with Structured Alpha. BitNil...
2023-07-11 13:19:00 ET Gainers: Eloxx Pharmaceuticals ( ELOX ) +112% . CytoMed Therapeutics Limited ( GDTC ) +102% . Biodexa Pharmaceuticals ( BDRX ) +92% . SOS Limited ( SOS ) +39% . Freeline Therapeutics Holdings ( FRLN ) +33% ...
FLT201 is a highly differentiated AAV gene therapy candidate that delivers a longer-acting engineered variant of GCase, the enzyme missing in people with Gaucher disease Company expects to report initial clinical data for FLT201 in third quarter of 2023 Parkinson’s diseas...
LONDON, June 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that its Chief Executive Officer Michael Parini will present at the 2023 Jefferies Healthcare Conference being held in New York on June 7-9, 2023. The presentation will ...
Please find enclosed the presentation of Frontline plc´s first quarter 2023 results to be held on the webcast / conference call 31 May, 2023 at 15:00 CET. This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Ac...
FRONTLINE PLC REPORTS RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2023 Frontline plc (the “Company” or “Frontline”), today reported unaudited results for the three months ended March 31, 2023: Highlights Highest first quarter profit sinc...
News, Short Squeeze, Breakout and More Instantly...
Freeline Therapeutics Holdings plc Company Name:
FRLN Stock Symbol:
NASDAQ Market:
Freeline Therapeutics Holdings plc Website:
Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline’s GBA1 Parkinson’s disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the...
BioHarvest Sciences Inc (CNVCF) is expected to report for quarter end 2023-12-31 QS Energy Inc (QSEP) is expected to report for Q4 2023 NKGen Biotech Inc. (NKGN) is expected to report for Q4 2023 Cal-Maine Foods Inc. (CALM) is expected to report for Q3 2024 Davide Campari (DVDCF) ...
Please find enclosed the presentation of Frontline plc´s fourth quarter 2023 results to be held on the webcast / conference call 29 February, 2024 at 15:00 CET. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act ...